Journal of the American Society of Nephrology, Vol 5, 1139-1146, Copyright © 1994 by American Society of Nephrology

REGULAR ARTICLES

Evidence that an angiotensin-converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started

N Perico, SC Amuchastegui, V Colosio, G Sonzogni, T Bertani and G Remuzzi
Mario Negri Institute for Pharmacological Research, Bergamo, Italy.

In rats with streptozotocin-induced diabetes, the effect of an angiotensin-converting enzyme (ACE) inhibitor on the evolution of glomerular injury according to the time at which the treatment is started with respect to the onset of the disease was studied. Three groups of animals were used, a control Group 1 and two groups of diabetic rats treated with insulin (Groups 2 and 3). The latter were monitored until urinary protein excretion reached 40 to 50 mg/24 h (on average, 23 wk after the induction of the diabetes). At this time, Group 2 continued to receive insulin alone, whereas Group 3 was also given the ACE inhibitor moexipril for 8 more wk. Untreated diabetic rats showed a moderate increase in systolic blood pressure that was normalized by moexipril administration. Urinary protein excretion progressively increased during the 8-wk follow-up in untreated diabetics that, at the end of the study, developed moderate glomerular sclerosis. Moexipril treatment lowered urinary protein excretion to a normal range and completely prevented glomerular injury. Three other groups of rats were similarly treated, except that moexipril treatment was started later on (when proteinuria reached 100 to 200 mg/24 h, on average, 32 wk after the induction of diabetes), and were monitored for another 8 wk. Untreated and treated diabetics had comparable blood glucose levels throughout. Systolic blood pressure, significantly increased in untreated diabetic rats, was effectively controlled by moexipril administration.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				G. Yasuda, D. Ando, N. Hirawa, S. Umemura, and O. Tochikubo Effects of Losartan and Amlodipine on Urinary Albumin Excretion and Ambulatory Blood Pressure in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy Diabetes Care, August 1, 2005; 28(8): 1862 - 1868. [Abstract] [Full Text] [PDF]

				S. G. Chrysant and G. S. Chrysant Pharmacological and Clinical Profile of Moexipril: A Concise Review J. Clin. Pharmacol., August 1, 2004; 44(8): 827 - 836. [Abstract] [Full Text] [PDF]

				A. Benigni, C. Zoja, D. Corna, C. Zatelli, S. Conti, M. Campana, E. Gagliardini, D. Rottoli, C. Zanchi, M. Abbate, et al. Add-On Anti-TGF-{beta} Antibody to ACE Inhibitor Arrests Progressive Diabetic Nephropathy in the Rat J. Am. Soc. Nephrol., July 1, 2003; 14(7): 1816 - 1824. [Abstract] [Full Text] [PDF]

				G. D Laverman, D. de Zeeuw, and G. Navis Between-patient differences in the renal response to renin-angiotensin system intervention: clue to optimising renoprotective therapy? Journal of Renin-Angiotensin-Aldosterone System, December 1, 2002; 3(4): 205 - 213. [Abstract] [PDF]

				C. Zoja, D. Corna, D. Camozzi, D. Cattaneo, D. Rottoli, C. Batani, C. Zanchi, M. Abbate, and G. Remuzzi How To Fully Protect the Kidney in a Severe Model of Progressive Nephropathy: A Multidrug Approach J. Am. Soc. Nephrol., December 1, 2002; 13(12): 2898 - 2908. [Abstract] [Full Text] [PDF]

				H. Bos, R. H. Henning, P. E. de Jong, D. de Zeeuw, and G. Navis Do severe systemic sequelae of proteinuria modulate the antiproteinuric response to chronic ACE inhibition? Nephrol. Dial. Transplant., May 1, 2002; 17(5): 793 - 797. [Abstract] [Full Text] [PDF]

				S. A. Mifsud, S. L. Skinner, M. E. Cooper, D. J. Kelly, and J. L. Wilkinson-Berka Effects of Low-Dose and Early versus Late Perindopril Treatment on the Progression of Severe Diabetic Nephropathy in (mREN-2)27 Rats J. Am. Soc. Nephrol., March 1, 2002; 13(3): 684 - 692. [Abstract] [Full Text] [PDF]

				G. Guo, J. Morrissey, R. McCracken, T. Tolley, H. Liapis, and S. Klahr Contributions of angiotensin II and tumor necrosis factor-{alpha} to the development of renal fibrosis Am J Physiol Renal Physiol, May 1, 2001; 280(5): F777 - F785. [Abstract] [Full Text] [PDF]

				P. Ruggenenti and G. Remuzzi Nephropathy of type 1 and type 2 diabetes: diverse pathophysiology, same treatment? Nephrol. Dial. Transplant., December 1, 2000; 15(12): 1900 - 1902. [Full Text] [PDF]

				E. L. A. Blezer, K. Nicolay, P. R. D. Bar, R. Goldschmeding, G. H. Jansen, H. A. Koomans, J. A. Joles, and F. M. Faraci Enalapril Prevents Imminent and Reduces Manifest Cerebral Edema in Stroke-Prone Hypertensive Rats • Editorial Comment Stroke, August 1, 1998; 29(8): 1671 - 1678. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673